目的研讨电化学发光免疫分析技术(ECLIA)在泌尿系统肿瘤诊治中的作用。方法对泌尿系统肿瘤的40例患者为甲组、急性尿路感染的45例患者为乙组,健康受检者42例为丙组,采用电化学发光免疫分析技术,对尿液中的CK19片段的含量进行检测,对其中一部分的患者采取动态的检测方法。结果以99%的可信度,标准界定为尿CK19的临界值3.9μg/L,其中甲组患者CK19检测阳性率为93.93%,乙组患者CK19检测阳性率为53.3%,丙组患者CK19检测无1例阳性表现。随意抽取患者20例进行1个月CK19的动态观察,其中有13例检测结果下降,升高7例。经临床检查确诊13例CK19检测结果下降的患者,均被确诊为尿路感染,检测结果升高的7例,有6例为膀胱的移行细胞癌,克隆病侵润伴有尿路感染1例。结论进行尿CK19片段的动态观察含量的变化,能减少急性尿路感染检测的假阳性率,增加尿CK19片段进行泌尿系统肿瘤的诊断意义。 Objective To investigate the role of electrochemiluminescence immunoassay (ECLIA) in the diagnosis and treatment of urological tumors. Methods Forty patients with urinary tract tumor were Group A, 45 patients with acute urinary tract infection were Group B and 42 healthy subjects were Group C. Electrochemiluminescence immunoassay was used to detect CK19 fragment in urine Of the content of detection, some of the patients to take dynamic detection methods. The results of 99% confidence level, the standard definition of urinary CK19 threshold of 3.9μg / L, of which CK19 positive in group A was 93.93%, CK19 positive in group B was 53.3%, CK19 in group C None of the positive cases. Twenty patients were randomly selected for dynamic observation of CK19 for one month. Among them, 13 cases had a decreased test result and an increase of 7 cases. Thirteen patients with clinically diagnosed CK19 test results were all diagnosed as urinary tract infection. Seven patients were diagnosed as having bladder cancer, six patients had bladder transitional cell carcinoma, one patient had urinary tract infection . Conclusions The change of the content of CK19 fragment in dynamic observation can reduce the false positive rate of acute urinary tract infection and increase the diagnostic value of urine CK19 fragment in urological tumors.